Humanigen Announces ZUMA-19 Abstract Accepted for Presentation at American Society of Hematology 2020 Annual Meeting

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (Nasdaq:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ by neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) with its lead therapeutic candidate lenzilumab™, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, today announced the acceptance of an abstract describing the ongoing ZUMA-19 study for presenta

Click to view original post